President Donald Trump signed an executive order this week setting a 30-day deadline for drugmakers to electively lower ...

In April 2025, the Company announced that the first patient had been dosed in Part 2a of the Phase 2 DENALI clinical trial ( NCT05128825) of azenosertib in patients with Cyclin E1+ platinum-resistant ...

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...

Q1 2025 Earnings Call Transcript May 12, 2025 Xenon Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.83, ...

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on the research and commercialization of ketamine ...

Inozyme recently featured new clinical insights and hosted an educational symposium at the Joint Congress of the European ...

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type ...

Obicetrapib monotherapy significantly improved the lipid profile of patients with heterozygous familial hypercholesterolemia ...

Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM)Manage ...

An executive order from President Trump aims to make deep cuts to prescription drug costs, putting GOP lawmakers who have ...

TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 ...